Wall Street analyst estimates for Jupiter Neurosciences, Inc. (JUNS): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues.
Valuation Ratios
| Price / Book | -4.27 |
| EV / EBITDA | -0.19 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | $1.1M | $638037 | $233281 | 0 | 0 | $21796 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 | $4231 |
| Gross Profit | 0 | $1.1M | $638037 | $233281 | 0 | 0 | $17565 |
| Research & Development | $685741 | $1.6M | $1.4M | $942806 | $954793 | $492660 | $2.1M |
| Selling, General & Admin | $1.5M | $1.3M | $3.1M | $2.7M | $2.9M | $2.6M | $6.8M |
| Operating Expenses | $2.2M | $3.0M | $4.5M | $3.7M | $3.9M | $3.1M | $8.9M |
| Operating Income | -$2.2M | -$1.9M | -$3.9M | -$3.4M | -$3.9M | -$3.1M | -$8.9M |
| EBITDA | -$2.7M | -$1.6M | -$4.1M | -$4.2M | -$4.6M | -$2.2M | -$8.6M |
| Interest Expense | $317104 | $13535 | $113994 | $740854 | $218705 | $248366 | $66020 |
| Pre-tax Income | -$3.0M | -$1.7M | -$4.2M | -$5.0M | -$4.8M | -$2.4M | -$8.6M |
| Income Tax | 0 | 0 | $179168 | 0 | 0 | 0 | 0 |
| Net Income | -$3.0M | -$1.7M | -$4.4M | -$5.0M | -$4.8M | -$2.4M | -$8.6M |
| EPS | $-26.25 | $-14.25 | $-33.00 | $-11.25 | $-10.50 | $-6.36 | $-18.75 |
| EPS (Diluted) | $-26.25 | $-14.25 | $-33.00 | $-11.25 | $-10.50 | $-6.36 | $-18.75 |
| Shares Outstanding (Diluted) | $116511 | $116511 | $126489 | $438352 | $438352 | $383774 | $461715 |
Price
| Price | $2.93 |
| Market Cap | $1M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ABVC · ALGS · FGEN · GNTA · GRCE · KZR · MRSN
Explore sector: Healthcare · Biotechnology
More sections of JUNS: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks